Stereotactic body radiotherapy with CyberKnife(®) System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

SIMPLE SUMMARY: Stereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Borzillo, Valentina, Scipilliti, Esmeralda, Pezzulla, Donato, Serra, Marcello, Ametrano, Gianluca, Quarto, Giuseppe, Perdonà, Sisto, Rossetti, Sabrina, Pignata, Sandro, Crispo, Anna, Di Gennaro, Piergiacomo, D’Alesio, Valentina, Arrichiello, Cecilia, Buonanno, Francesca, Mercogliano, Simona, Russo, Antonio, Tufano, Antonio, Di Franco, Rossella, Muto, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660677/
https://www.ncbi.nlm.nih.gov/pubmed/38023175
http://dx.doi.org/10.3389/fonc.2023.1270498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660677/
https://www.ncbi.nlm.nih.gov/pubmed/38023175
http://dx.doi.org/10.3389/fonc.2023.1270498

Ejemplares similares